Published March 2, 2018 | Version v1
Dataset Open

Determining CD34 expression in the presence and absence of stroma

  • 1. Structural Genomics Consortium, Princess Margaret Cancer Centre, University Health Network
  • 2. Structural Genomics Consortium, University of Toronto
  • 3. Princess Margaret Cancer Centre, University Health Network, University of Toronto
  • 4. Structural Genomics Consortium, Princess Margaret Cancer Centre, University Health Network, University of Toronto

Description

Determining whether OCI-AML-20 cells require stroma for CD34 expression.

Notes

The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome [106169/ZZ14/Z]. This project receives funding from the Leukemia and Lymphoma Society of Canada.

Files

2-22-18_CD34_presence_and_absence_stroma.pdf

Files (1.0 MB)

Name Size Download all
md5:f6367f6727eafecf07e47deb764c3db3
640.5 kB Download
md5:5c7c6143947f99c4638e4d27646c2adb
375.2 kB Preview Download